However, in light of the heterogeneity of AD phenotypes and ongoing debates concerning the roles of Aβ oligomers and plaques, we propose that further investigation into the products of non‐canonical APP processing and their potential interactions with canonical Aβ peptides is warranted in AD pathogenesis. The gene discussed is APP; the disease is Alzheimer disease.